The goal of this clinical trial is to find out whether Iron (III)-hydroxide polymaltose complex (IPC) given on an alternate-day schedule works as well as daily dosing in treating iron deficiency anaemia in children. The study will also look at the safety and tolerability of IPC.
The main questions this study aims to answer are:
Does alternate-day oral IPC improve haemoglobin levels and serum ferritin level as effectively as daily oral IPC?
Does alternate-day dosing reduce gastrointestinal side effects compared to daily dosing?
Does alternate-day dosing improve treatment adherence in children?
Researchers will compare alternate-day IPC with daily IPC to determine the most effective and well-tolerated dosing schedule for children with iron deficiency anaemia.
Participants will:
Receive oral Iron (III)-hydroxide polymaltose complex either daily or on alternate days for 12 weeks treatment period
Attend regular clinic visits for clinical assessment and blood investigations
Be monitored for adverse effects, adherence to treatment, and improvement in haemoglobin and serum ferritin levels
None
Critically ill child
Children with documented chronic illnesses (e.g., known renal failure, known liver disease)
Children with known cases of thalassemia
Children with severe anaemia requiring transfusion